Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.

Tamai H, Shioi Y, Yamaguchi H, Okabe M, Wakita S, Mizuki T, Nakayama K, Inokuchi K, Tajika K, Dan K.

Leukemia. 2008 Jun;22(6):1273-4. Epub 2007 Nov 8. No abstract available.

PMID:
17989711
2.

Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.

Tachibana T, Tanaka M, Takasaki H, Numata A, Fujisawa S, Maruta A, Harada H, Mori H, Ishigatsubo Y, Kanamori H.

Int J Hematol. 2011 Dec;94(6):580-2. doi: 10.1007/s12185-011-0967-8. Epub 2011 Dec 2. No abstract available.

PMID:
22135078
3.

Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.

Asano H, Yamamoto G, Hosoi M, Takahashi T, Hangaishi A, Kurokawa M.

Leuk Res. 2010 Jul;34(7):e152-3. doi: 10.1016/j.leukres.2009.12.006. Epub 2010 Jan 12. No abstract available.

PMID:
20061019
4.

Nine years interval between first and second bone marrow transplantations and subsequent long-term survival--a case of acute myeloid leukemia with MLL-AF6 fusion gene.

Yokoyama Y, Suzukawa K, Okoshi Y, Nanmoku T, Obara N, Enami T, Hasegawa Y, Chiba S.

Ann Hematol. 2012 Sep;91(9):1491-3. doi: 10.1007/s00277-012-1417-2. Epub 2012 Feb 4. No abstract available.

PMID:
22307741
5.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2001 Jun;7(6):1490-6. Erratum in: Clin Cancer Res 2002 Jan;8(1):300.

6.

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.

Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, Foley S, Satwani P, Unal E, Bhatia M, Bradley B, Del Toro G, George D, Garvin J, van de Ven C, Cairo MS.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7164s-7170s.

7.

Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.

El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, Bazarbachi A.

Leuk Res. 2009 Apr;33(4):565-6. doi: 10.1016/j.leukres.2008.05.006. Epub 2008 Jun 20. No abstract available.

PMID:
18571231
8.

Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.

Wang ES, Zeidan A, Tan W, Wilding GE, Ford LA, Wallace PK, Hahn TE, Battiwalla M, McCarthy PL, Wetzler M.

Leuk Lymphoma. 2012 Oct;53(10):2085-8. doi: 10.3109/10428194.2011.603450. Epub 2011 Sep 6. No abstract available.

PMID:
21740302
9.

Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.

Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, Tanizawa Y.

Tohoku J Exp Med. 2010 Feb;220(2):121-6.

10.

Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.

Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A.

Nat Clin Pract Oncol. 2007 Aug;4(8):491-5.

PMID:
17657254
11.

Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.

Unal S, Cakir M, Kuşkonmaz B, Cetin M, Tuncer AM.

Turk J Pediatr. 2009 Jan-Feb;51(1):69-71.

PMID:
19378895
12.

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS.

Blood. 2011 May 19;117(20):5306-13. doi: 10.1182/blood-2010-09-309229. Epub 2011 Mar 17.

13.

Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.

Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Ronconi S, Visani G, Baccarani M.

Haematologica. 2003 Dec;88(12):ECR37. No abstract available.

14.

Dismal long-term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now?

Sibson K, Steward C, Moppett J, Cornish J, Goulden N.

Br J Haematol. 2009 Aug;146(3):342-4. doi: 10.1111/j.1365-2141.2009.07750.x. Epub 2009 May 26. No abstract available.

PMID:
19545292
15.

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, Lode L, Richebourg S, Blanchet O, Vey N, Ifrah N, Milpied N, Blaise D, Harousseau JL, Mohty M.

Leukemia. 2010 Feb;24(2):467-9. doi: 10.1038/leu.2009.214. Epub 2009 Oct 22. No abstract available.

PMID:
19847200
16.

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.

Stasi R.

Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527 . Review.

PMID:
18352855
17.

Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.

Radsak MP, Salih HR, Sökler M, Kanz L, Denzlinger C.

Leukemia. 2002 Sep;16(9):1870-1. No abstract available.

18.

Treatment of relapsed or refractory acute promyelocytic leukemia.

Tallman MS.

Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65. Review.

PMID:
17336255
19.

Treatment of refractory and relapsed acute myelogenous leukemia.

Stanisic S, Kalaycio M.

Expert Rev Anticancer Ther. 2002 Jun;2(3):287-95. Review.

PMID:
12113052
20.

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.

Ichikawa M, Hangaishi A, Nannya Y, Kurokawa M.

Int J Hematol. 2010 Nov;92(4):673-4. doi: 10.1007/s12185-010-0711-9. Epub 2010 Oct 28. No abstract available.

PMID:
20978876

Supplemental Content

Support Center